Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)

Completed · Phase 2/Phase 3

Conditions studied: Vitreous Hemorrhage, Proliferative Diabetic Retinopathy

In brief

This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage from proliferative diabetic retinopathy.

Key facts

Study ID
NCT00996437
Run by
Jaeb Center for Health Research
People needed
261
Starts
2010-06-01
Expected to finish
2013-01-01
Last updated by the study team
2016-08-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.